Modern antifungal therapy for neutropenic fever.


Empirical antifungal therapy has been shown to decrease the number of documented fungal infections in the setting of persistent fever during neutropenia. For decades, amphotericin B deoxycholate has been considered the agent of choice for first-line therapy in this setting. New antifungal agents associated with less toxicity, including the lipid… (More)
DOI: 10.1007/s11899-006-0029-0